Cisbio to Display Newest Innovations for Oncology Drug Discovery at AACR 2014
20 Mar 2014

Join Cisbio as they show you how they are “Building Better Assays” at the 2014 AACR Annual Meeting to be held April 5-9 in San Diego, California. The company’s commitment to provide novel assays, based on their patented HTRF® technology, to meet the evolving needs of oncology drug discovery researchers is reflected in the new products they are launching at this conference. Cisbio is excited to showcase their newest innovations at Booth #1748.

Cisbio will be introducing a number of new cellular assays at the conference. HTRF cellular phospho-protein and cell signaling assays provide precise, sensitive measurement of the level of phosphorylated and non-phosphorylated proteins that can be achieved in an endogenous cellular environment. All assays are based on the same sandwich immunoassay construction, comprising two specific monoclonal antibodies coupled to HTRF donor and acceptor dyes. Stop by their booth to learn more about their new HTRF cellular phospho-protein assays and their flexible implementation on the CyBi®-FeliX, a compact liquid handling platform, for an ideal automated cellular phospho-readout to simplify pathway investigation.

Cisbio will also be presenting their EPIgeneous™ products, a line of validated, HTRF assay kits and toolbox reagents for reliable, high throughput screening and investigation of epigenetic targets. Rapid advancements have been made in understanding the key role epigenetic modifications play in regulating cell activity and their implications on cell health and disease progression. This knowledge led to a growing interest in exploring epigenetic enzymes and proteins, such as histone methyltransferases (HMT), demethylases (HDMT), deacetylases (HDAC) and acetylases (HAT) as drugable targets. The newest additions to the Cisbio EPIgeneous product line for high sensitivity screening of epigenetic modifications, will be highlighted at the AACR Annual Meeting, including cellular epigenetic assays, a universal methyltransferase assay and epigenetic toolbox reagents.

Come explore the benefits of HTRF technology and see how Cisbio’s broad portfolio of fast and easy mix-and-read assays could simplify your life and dramatically increase throughput and productivity in your lab. Talk to them in person. Witness their technology in action. And experience what they mean by “Interaction Is Everything”. Click on the company website link to learn more about all of their new kits and reagents.

Request Info


Company website

Cisbio Bioassays
profile photo

Sarah Thomas
Editorial Assistant